ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 577,22
-0,73%
Dow Jones
40 711,67
1,24%
DAX
18 498,92
-0,54%
Brent Oil
83,03
-1,55%
Bitcoin
63 729,92
-1,73%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
04/11/200814h00Business WireAllos Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/10/200822h06Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/10/200821h00Business WireFour Pralatrexate (PDX) Studies Accepted for Presentation at the 50th Annual Meeting of the American Society of HematologyNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/10/200813h00Business WireAllos Therapeutics to Report Third Quarter 2008 Results on November 5, 2008NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/10/200814h00Business WireAllos Therapeutics to Present at the JMP Healthcare Focus ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/09/200815h05Edgar (US Regulatory)Allos Therapeutics Inc - Confidential Treatment Order (CT ORDER)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/09/200823h06Edgar (US Regulatory)Allos Therapeutics Inc - Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/09/200814h00Business WireAllos Therapeutics to Present at the 3rd Annual Citi Biotech DayNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/08/200822h00Business WireAllos Therapeutics to Present at the NewsMakers in the Biotech Industry ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/08/200822h17Edgar (US Regulatory)Allos Therapeutics Inc - Amended Annual Report (10-K/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/08/200823h30Edgar (US Regulatory)Allos Therapeutics Inc - Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/08/200822h03Edgar (US Regulatory)Allos Therapeutics Inc - Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/08/200822h00Business WireAllos Therapeutics Reports 2008 Second Quarter ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/07/200814h00Business WireAllos Therapeutics to Present at the Bank of America 2008 Specialty Pharmaceuticals ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/07/200814h00Business WireAllos Therapeutics to Report Second Quarter 2008 Results on August 5, 2008NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
21/07/200814h00Business WireAllos Therapeutics Initiates Phase 2 Study of PDX in Patients with Advanced or Metastatic Relapsed Transitional Cell Carcinoma oNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/07/200814h00Business WireAllos Therapeutics to Present at the Collins Stewart Fourth Annual Growth ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/06/200821h55Edgar (US Regulatory)Allos Therapeutics Inc - Securities Registration: Employee Benefit Plan (S-8)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/06/200821h52Edgar (US Regulatory)Allos Therapeutics Inc - Post-Effective Amendment to an S-8 filing (S-8 POS)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/06/200813h00Business WireAllos Therapeutics to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/06/200821h00Business WireAllos Therapeutics Announces Interim Data from Phase 1 Study of PDX in Patients with Relapsed or Refractory Cutaneous T-Cell LymNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/05/200822h05Edgar (US Regulatory)Allos Therapeutics Inc - Amended Statement of Beneficial Ownership (SC 13D/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/05/200817h15Edgar (US Regulatory)Allos Therapeutics Inc - Statement of Ownership (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/05/200821h00Business WireAllos Therapeutics Announces Closing of Public Common Stock OfferingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/05/200813h25Edgar (US Regulatory)Allos Therapeutics Inc - Prospectus filed pursuant to Rule 424(b)(5) (424B5)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/05/200813h15Edgar (US Regulatory)Allos Therapeutics Inc - Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/05/200812h34Business WireAllos Therapeutics Announces Pricing of Public Offering of 10,800,000 Shares of Common StockNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/05/200812h41Business WireAllos Therapeutics Announces Public Offering of 9,000,000 Shares of Common StockNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/05/200812h00Business WireAllos Therapeutics Reports Interim Response and Safety Data from Pivotal Phase 2 PROPEL TrialNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/05/200813h30Business WireAllos Therapeutics Reports First Quarter 2008 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

USOTC
LVCA
Victoria Lake (CE)
NASDAQ
SNDL
Sundial Growers
NYSE
SVR
Syniverse Hlgs
NASDAQ
ADI
Analog Devices
NASDAQ
EXFO
EXFO
NASDAQ
ALTH
NASDAQ
SATC
NYSE
DRII
DIAMOND RESORTS INTERNATIONAL, I
USOTC
PSTRQ
PostRock Energy (CE)
NYSE
HMN
Horace Mann Educators
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés